Pediatric Clinics of North America - CIPERJ

More documents

Recommendations

Info

444 FASANO & LUBAN [20] Roseff SD, Luban NL, Manno CS. Guidelines for assessing appropriateness of pediatric transfusion. Transfusion 2002;42:1398–413. [21] Robitaille N, Hume HA. Blood components and fractionated plasma products: preparations, indications, and administration. In: Arceci RJ, Hann IM, Smith OP, editors. Pediatric hematology. 3rd edition. New York: Wiley Blackwell; 2006. p. 693–706. [22] Vichinsky EP, Haberkern CM, Neumayer L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med 1995;333:206–13. [23] Scotborn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 2002;140:348–54. [24] Adams RJ, McKie VC, Hsu L, et al. Prevention of first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonagraphy. N Engl J Med 1998;339:5–11. [25] Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769–78. [26] Smith-Whitley K. Alloimmunization in patients with sickle cell disease. In: Manno CS, editor. Pediatric transfusion therapy. Bethesda (MD): AABB Press; 2002. p. 249–82. [27] Vichinsky EP, Luban NC, Wright E, et al. Prospective RBC phenotype matching in a strokeprevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion 2001;41: 1086–92. [28] Alloimmune cytopenias. In: Roseff SD, editor. Pediatric transfusion: a physician’s handbook. 2nd edition. Bethesda (MD): American Association of Blood Banks; 2006. p. 53–97. [29] British Committee for Standards in Hematology, Blood Transfusion Task Force. Transfusion guidelines for neonates and older children. Br J Haematol 2004;124:433–53. [30] Kirpalani H, Whyte RK, Anderson C, et al. The Premature Infants in Need of Transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr 2006;149:301–7. [31] Bell EF, Strauss RG, Widness JA, et al. Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. J Pediatr 2005;115:1685–91. [32] Cid J, Lozano M. Risk of Rh(D) alloimmunization after transfusion of platelets from Dþ donors to D- recipients. Transfusion 2005;45:453. [33] Klein HG, Anstee DJ, editors. Mollison’s blood transfusion in clinical medicine. 11th edition. Blackwell; 2005. p. 187–91. [34] Molnar R, Johnson R, Sweat LT, et al. Absence of D alloimmunization in D- pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion 2002;42: 177–82. [35] Gil-Fernandez JJ, Alegre A, FernandezVillalta MJ, et al. Clinical results of a stringent policy on prophylactic platelet transfusion: Non-randomized comparative analysis of 190 bone marrow transplant patients from a single institution. Bone Marrow Transplant 1996;18: 931–5. [36] Heckman KD, Weiner GJ, Davis CS. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000 microL versus 20,000 microL. J Clin Oncol 1997;15:1143–9. [37] Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of 10 x 109/L trigger for prophylactic platelet transfusion compared with the traditional 20 x 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998;91:3601–6. [38] Murray NA, Horwarth LJ, McCloy MP, et al. Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients. Transfus Med 2002;12: 35–41. [39] Vassallo RR. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol 2007;14:655–63.
BLOOD COMPONENT THERAPY 445 [40] Perotta PL, Pisciotto PT, Snyder EL. Platelets and related products. In: Hillyer CD, Silberstein LE, Ness PM, et al, editors. Blood banking and transfusion medicine basic principles and practice. 1st edition. Philadelphia: Churchill Livingstone; 2003. p. 181–206. [41] Petz LD, Garatty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000;40:1446–56. [42] Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev 2000;14:180–96. [43] British Committee for Standards in Hematology, Blood Transfusion Task Force. Amendments and corrections to the ‘transfusion guidelines for neonates and older children’ (BCSH, 2004a); and to the ‘Guidelines for the use of fresh frozen plasma, cryoprecipitate and cryosupernatent’ (BCSH, 2004b). Br J Haematol 2006;136:514–6. [44] Mathew P. The use of rVIIa in non-hemophilia bleeding conditions in paediatrics. A systematic review. Thromb Haemost 2004;92:738–46. [45] Mathew P, Young G. Recombinant factor VIIa in paediatric bleeding disordersda 2006 review. Haemophilia 2006;12:457–72. [46] Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999;5(Suppl 3):11–7. [47] Mohan P, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev 2003;4:CD003956. [48] Bishton M, Chopra R. The role of granulocyte transfusions in neutropenic patients. Br J Haematol 2004;127:501–8. [49] Vamvakas EC, Pineda AA. Determinants of the efficacy of prophylactic granulocyte transfusions: a meta-analysis. J Clin Apheresis 1997;12:74–81. [50] Sanders RP, Maddirala SD, Geiger TL, et al. Premedication with acetaminophen or diphenhydramine for transfusion with leucoreduced blood products in children. Br J Haematol 2005;130:781–7. [51] Davenport RD. Hemolytic transfusion reactions. In: Popovsky MA, editor. Transfusion reactions. 3rd edition. 2007. p. 1–56. [52] Kopko PM, Popovsky MA. Transfusion related acute lung injury. In: Popovsky MA, editor. Transfusion reactions. 3rd edition. 2007. p. 207–28. [53] Sanchez R, Toy P. Transfusion related acute lung injury: a pediatric perspective. Pediatr Blood Cancer 2005;45:248–55. [54] Silliman CC, Boshkov LK, Meddizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003;101:454–62. [55] Serious Hazards of Transfusion (SHOT). Annual report. 2006. Manchester, UK: SHOT Scheme, 2006. Available at: http://www.shotuk.org/SHOTREPORT2006.PDF. Accessed March 12, 2008. [56] Eder AF, Herron R, Strupp A, et al. Transfusion related acute lung injury surveillance (2003–2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007;47:599–607. [57] Transfusion-related acute lung injury Association bulletin #06-07. Bethesda (MD): AABB; 2006. Available at: http://www.aabb.org/content/Members_Area/Association_Bulleins/ ab06-07.htm. Accessed March 12, 2008.
Page 2 and 3:
Pediatr Clin N Am 55 (2008) xiii-xi
Page 4 and 5:
Pediatr Clin N Am 55 (2008) 287-304
Page 6 and 7:
DECISION ANALYSIS IN PEDIATRIC HEMA
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Nietert et al [30] Treatment of sic
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
VENOUS THROMBOEMBOLISM IN CHILDREN
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
PEDIATRIC ARTERIAL ISCHEMIC STROKE
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
CARE OF PATIENTS WITH VASCULAR ANOM
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
358 RODRIGUEZ & HOOTS Fig. 1. X-lin
Page 76 and 77:
Table 1 Clotting factor concentrate
Page 78 and 79:
Table 1 (continued ) Factor VIII (o
Page 80 and 81:
364 RODRIGUEZ & HOOTS was administe
Page 82 and 83:
366 RODRIGUEZ & HOOTS Antifibrinoly
Page 84 and 85:
368 RODRIGUEZ & HOOTS infections an
Page 86 and 87:
370 RODRIGUEZ & HOOTS Fig. 3. Schem
Page 88 and 89:
372 RODRIGUEZ & HOOTS protein is no
Page 90 and 91:
374 RODRIGUEZ & HOOTS [2] Berntorp
Page 92 and 93:
376 RODRIGUEZ & HOOTS [42] Carcao M
Page 94 and 95:
378 ROBERTSON et al von Willebrand
Page 96 and 97:
380 ROBERTSON et al Fig. 2. A propo
Page 98 and 99:
382 ROBERTSON et al a heterogenous
Page 100 and 101:
384 ROBERTSON et al of considering
Page 102 and 103:
386 ROBERTSON et al Type 2M Type 2M
Page 104 and 105:
388 ROBERTSON et al Desmopressin is
Page 106 and 107:
390 ROBERTSON et al References [1]
Page 108 and 109:
392 ROBERTSON et al [46] Nesbitt IM
Page 110 and 111: 394 BLANCHETTE & BOLTON-MAGGS A key
Page 112 and 113: 396 BLANCHETTE & BOLTON-MAGGS recep
Page 114 and 115: 398 BLANCHETTE & BOLTON-MAGGS and p
Page 116 and 117: 400 BLANCHETTE & BOLTON-MAGGS Fig.
Page 118 and 119: 402 BLANCHETTE & BOLTON-MAGGS in di
Page 120 and 121: 404 BLANCHETTE & BOLTON-MAGGS the s
Page 122 and 123: 406 BLANCHETTE & BOLTON-MAGGS findi
Page 124 and 125: 408 BLANCHETTE & BOLTON-MAGGS as a
Page 126 and 127: 410 BLANCHETTE & BOLTON-MAGGS splen
Page 128 and 129: 412 BLANCHETTE & BOLTON-MAGGS with
Page 130 and 131: 414 BLANCHETTE & BOLTON-MAGGS react
Page 132 and 133: 416 BLANCHETTE & BOLTON-MAGGS [16]
Page 138 and 139: 422 FASANO & LUBAN of storage and t
Page 140 and 141: 424 FASANO & LUBAN Leukocyte reduct
Page 142 and 143: 426 FASANO & LUBAN RBCs is decrease
Page 144 and 145: Table 1 Blood component characteris
Page 146 and 147: 430 FASANO & LUBAN Alloimmunization
Page 148 and 149: 432 FASANO & LUBAN of individual un
Page 150 and 151: 434 FASANO & LUBAN patients have an
Page 152 and 153: 436 FASANO & LUBAN adults; therefor
Page 154 and 155: 438 FASANO & LUBAN [21]. Meta-analy
Page 156 and 157: 440 FASANO & LUBAN Pretransfusion m
Page 158 and 159: 442 FASANO & LUBAN [55,56]. This is
Page 162 and 163: Pediatr Clin N Am 55 (2008) 447-460
Page 164 and 165: THALASSEMIA UPDATE 449 hypochromia
Page 166 and 167: THALASSEMIA UPDATE 451 Fig. 1. Chan
Page 168 and 169: THALASSEMIA UPDATE 453 delivery of
Page 170 and 171: THALASSEMIA UPDATE 455 thromboses i
Page 172 and 173: THALASSEMIA UPDATE 457 On the basis
Page 174 and 175: THALASSEMIA UPDATE 459 [31] Kan YW,
Page 178 and 179: ORAL IRON CHELATORS 463 large iron-
Page 180 and 181: ORAL IRON CHELATORS 465 of 50 child
Page 182 and 183: ORAL IRON CHELATORS 467 Table 2 Com
Page 184 and 185: ORAL IRON CHELATORS 469 use in Nort
Page 186 and 187: ORAL IRON CHELATORS 471 needed to d
Page 188 and 189: ORAL IRON CHELATORS 473 in liver fi
Page 190 and 191: ORAL IRON CHELATORS 475 in the lowe
Page 192 and 193: ORAL IRON CHELATORS 477 Other oral
Page 194 and 195: ORAL IRON CHELATORS 479 [12] Borgna
Page 196 and 197: ORAL IRON CHELATORS 481 [55] Wonke
Page 200 and 201: HYDROXYUREA FOR CHILDREN WITH SICKL
Page 208 and 209: Fig. 1. Guideline for initiating, m
Page 210 and 211:
HYDROXYUREA FOR CHILDREN WITH SICKL
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
504 TRACY & RICE congenital spheroc
Page 220 and 221:
506 TRACY & RICE and antibodies aga
Page 222 and 223:
508 TRACY & RICE limited splenic vo
Page 224 and 225:
510 TRACY & RICE constitutes the pi
Page 226 and 227:
512 TRACY & RICE German experience
Page 228 and 229:
514 TRACY & RICE Table 1 Effect of
Page 230 and 231:
516 TRACY & RICE decreased bilirubi
Page 232 and 233:
518 TRACY & RICE [13] Bader-Meunier
show all

Pediatric Clinics of North America - CIPERJ

Create successful ePaper yourself

Delete template?

Save as template?